Thomas Graham, Alan, Irving Kahns
Kahn Brothers Group
Kahn Brothers Group GlaxoSmithKline PLC ADR stake
total: 111
Kahn Brothers Group GSK trades
- Total transactions:
- 45
- New positions:
- 1
- Added:
- 23
- Reduced:
- 21
- Held since:
- 2014 Q3
- Held for:
- 47 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Kahn Brothers Group holds 160,982 GlaxoSmithKline PLC ADR (GSK) shares with a market value of roughly $8.88M accounting for 1.58% of the overall portfolio. To date, the estimated cost basis is nearly $48.6 for "buy" trades and estimated average "sell" price is $42.09. Kahn Brothers Group first purchased GSK in 2014 Q3, initially acquiring 40,800 shares. Since the initial investment in GlaxoSmithKline PLC ADR (GSK), Kahn Brothers Group has made 44 more transactions.
When did Kahn Brothers Group buy GlaxoSmithKline PLC ADR (GSK)?
Kahn Brothers Group first invested in GlaxoSmithKline PLC ADR (GSK) in 2014 Q3 at the reported quarter-end price of $57.46 per share.
What's the cost basis of Kahn Brothers Group's GSK stake?
The estimated cost basis for GlaxoSmithKline PLC ADR (GSK) stake is around $48.60 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $48.60
- Weighted AVG sell price:
- $42.09
Kahn Brothers Group's historical trades in GlaxoSmithKline PLC ADR
45 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
1.58%
|
160,982
|
$55.19
|
$8,884,596
|
-9.91% (-17,714)
|
-0.17%
|
|
2025 Q4
|
1.55%
|
178,696
|
$49.04
|
$8,763,251
|
-31.49% (-82,141)
|
-0.76%
|
|
2025 Q3
|
2.12%
|
260,837
|
$43.16
|
$11,257,724
|
-60.47% (-399,035)
|
-3.46%
|
|
2025 Q2
|
5.09%
|
659,872
|
$38.40
|
$25,339,084
|
-19.75% (-162,355)
|
-1.26%
|
|
2025 Q1
|
6.44%
|
822,227
|
$38.74
|
$31,852,636
|
-7.06% (-62,481)
|
-0.53%
|
|
2024 Q4
|
6.50%
|
884,708
|
$33.82
|
$29,921,125
|
-16.44% (-174,124)
|
-1.01%
|
|
2024 Q3
|
7.46%
|
1,058,832
|
$40.88
|
$43,285,078
|
-14.70% (-182,429)
|
-1.25%
|
|
2024 Q2
|
8.03%
|
1,241,261
|
$38.50
|
$47,788,450
|
-0.99% (-12,383)
|
-0.07%
|
|
2024 Q1
|
7.97%
|
1,253,644
|
$42.87
|
$53,743,386
|
-0.46% (-5,838)
|
-0.04%
|
|
2023 Q4
|
7.35%
|
1,259,482
|
$37.06
|
$46,676,538
|
-1.78% (-22,807)
|
-0.13%
|
|
2023 Q3
|
7.25%
|
$36.25
|
+1.49% (+18,831)
|
|||
|
2023 Q2
|
6.60%
|
$35.64
|
-1.10% (-14,018)
|
|||
|
2023 Q1
|
6.54%
|
$35.58
|
+4.12% (+50,570)
|
|||
|
2022 Q4
|
5.68%
|
$35.14
|
-5.98% (-78,033)
|
|||
|
2022 Q3
|
5.98%
|
$29.43
|
+13.98% (+160,011)
|
|||
|
2022 Q2
|
8.39%
|
$54.41
|
+0.32% (+3,596.8)
|
|||
|
2022 Q1
|
7.89%
|
$54.45
|
-0.83% (-9,524)
|
|||
|
2021 Q4
|
8.71%
|
$55.12
|
+6.30% (+68,168.8)
|
|||
|
2021 Q3
|
7.28%
|
$47.76
|
+4.34% (+44,999.2)
|
|||
|
2021 Q2
|
7.40%
|
$49.78
|
+2.48% (+25,071.2)
|
|||
|
2021 Q1
|
6.99%
|
$44.61
|
-1.26% (-12,923.2)
|
|||
|
2020 Q4
|
8.23%
|
$46.00
|
-8.87% (-99,812)
|
|||
|
2020 Q3
|
10.04%
|
$47.05
|
-7.33% (-88,983.2)
|
|||
|
2020 Q2
|
10.51%
|
$51.22
|
-1.66% (-20,560)
|
|||
|
2020 Q1
|
10.70%
|
$47.36
|
-2.77% (-35,208)
|
|||
|
2019 Q4
|
9.05%
|
$58.74
|
-2.03% (-26,376.8)
|
|||
|
2019 Q3
|
8.67%
|
$53.35
|
+0.97% (+12,468)
|
|||
|
2019 Q2
|
8.03%
|
$50.02
|
+25.73% (+262,771.2)
|
|||
|
2019 Q1
|
8.33%
|
$52.24
|
+1.24% (+12,488)
|
|||
|
2018 Q4
|
8.69%
|
$47.76
|
+1.56% (+15,539.2)
|
|||
|
2018 Q3
|
7.66%
|
$50.21
|
+0.40% (+3,939.2)
|
|||
|
2018 Q2
|
7.93%
|
$50.39
|
+0.48% (+4,760)
|
|||
|
2018 Q1
|
7.66%
|
$48.84
|
+8.03% (+73,183.2)
|
|||
|
2017 Q4
|
6.35%
|
$44.34
|
+11.56% (+94,422.4)
|
|||
|
2017 Q3
|
6.33%
|
$50.75
|
-3.22% (-27,160)
|
|||
|
2017 Q2
|
6.94%
|
$53.90
|
+0.39% (+3,272)
|
|||
|
2017 Q1
|
7.62%
|
$52.70
|
+26.12% (+174,144)
|
|||
|
2016 Q4
|
5.42%
|
$48.14
|
+31.85% (+161,020)
|
|||
|
2016 Q3
|
4.96%
|
$54.11
|
+66.18% (+201,364)
|
|||
|
2016 Q2
|
3.19%
|
$54.18
|
+188.24% (+198,708)
|
|||
|
2016 Q1
|
1.00%
|
$50.69
|
+55.97% (+37,880)
|
|||
|
2015 Q4
|
0.61%
|
$50.44
|
+47.13% (+21,680)
|
|||
|
2015 Q3
|
0.41%
|
$48.06
|
-1.20% (-560)
|
|||
|
2015 Q1
|
0.45%
|
$57.69
|
+14.12% (+5,760)
|
|||
|
2014 Q3
|
0.38%
|
$57.46
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.